News | Nov 03, 2004
License to Roche Molecular Systems, Inc.
EPIDAUROS Biotechnologie AG, Bernried, Germany, grants commercial license to important polymorphism of drug metabolism gene to Roche Molecular Systems, Inc.
Bernried, Germany - 3 November 2004 - EPIDAUROS Biotechnologie AG, a pharmacogenetics company located in Bernried near Munich, is very pleased to announce it has granted a non-exclusive commercial license to its patent on a polymorphism of the promoter region of the CYP2D6 gene to Roche Molecular Systems, Inc. (RMS), of Pleasanton, California, USA. RMS uses the EPIDAUROS patent for discovery, production and commercialization of a multi-parameter diagnostic chip, the AmpliChip ® CYP450 Test *, which is now available for diagnostic use in the European Union.
The CYP2D6 gene codes for an enzyme that metabolizes approximately 25% of widely prescribed drugs. CYP2D6*41 is associated with reduced drug metabolism - and therefore increased plasma concentrations – which can lead to possible overdose and adverse drug reactions. Under the terms of the license agreement RMS will provide an upfront signing-fee and royalties on their commercial sales of the AmpliChip ® CYP450 Test.
„We are delighted to report this agreement, since it stands for a newer source of income for EPIDAUROS, namely the commercialization of our own IP", said Dr. Manfred Zoltobrocki, CEO of EPIDAUROS Biotechnologie AG. "We will continue to offer licenses and pursue negotiations with other possible out-licensing partners", Dr. Zoltobrocki continued.
Contact EPIDAUROS
Dr. Manfred Zoltobrocki
EPIDAUROS Biotechnologie AG
CEO
Phone: +49 (0)8158-9985-0
Fax: +49 (0)8158-9985-48
E-Mail: info@epidauros.com
File(s) | ||
 | Size: 47 K | |
- Links: